

This material is an English translation of the press release announced on November 9, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

November 9, 2018

**Notification of approval for manufacturing and marketing approval of  
OABLOK®PATCH in Taiwan  
(Transdermal, Overactive bladder treatment patch)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi) announces that Hisamitsu has acquired an approval of manufacturing and marketing permit for OABLOK®PATCH in Taiwan, transdermal, overactive bladder treatment patch.

This is a transdermal therapeutic formulation for oxybutynin hydrochloride developed as a patch-form drug using Hisamitsu's TDDS (transdermal drug delivery system) technology. The development was conducted with the expectation to sustain pharmacological effects by maintaining stable drug concentrations in the blood.

Hisamitsu are committed to further improving the quality of life of patients who suffer from overactive bladders in Taiwan by providing information on proper uses of this product.

Reference:

Trade name	OABLOK®PATCH
Active ingredient	Oxybutynin hydrochloride
Indication	Overactive bladder
Dose and Administration	For usual adult dose, apply 1 patch (73.5 mg as oxybutynin hydrochloride) of this drug once daily to the lower abdomen, lower back, or thigh, and change the patch every 24 hours.
Remarks	This product has been launch under the product name "Neoxy® tape 73.5 mg" in Japan since June 2013.